Hostname: page-component-7b7567c8c-z4zkx Total loading time: 0 Render date: 2026-11-16T16:20:20.198Z Has data issue: false hasContentIssue false

Pulmonary aspergillosis in US Veterans with COVID-19: a nationwide, retrospective cohort study

Published online by Cambridge University Press:  30 January 2025

Kaitlin Swinnerton
Affiliation:
VA Boston Cooperative Studies Program, Boston, MA, USA
Nathanael R. Fillmore
Affiliation:
VA Boston Cooperative Studies Program, Boston, MA, USADana Farber Cancer Institute, Boston, MA, USAHarvard Medical School, Boston, MA, USAVA Boston Healthcare System, Boston, MA, USA
Ikwo Oboho
Affiliation:
VA North Texas Health Care System, Dallas, TX, USAUT Southwestern School of Medicine, Dallas, TX, USA
Janet Grubber
Affiliation:
VA Boston Cooperative Studies Program, Boston, MA, USAVA Boston Healthcare System, Boston, MA, USA
Mary Brophy
Affiliation:
VA Boston Cooperative Studies Program, Boston, MA, USAVA Boston Healthcare System, Boston, MA, USABoston University School of Medicine, Boston, MA, USA
Nhan V Do
Affiliation:
VA Boston Cooperative Studies Program, Boston, MA, USAVA Boston Healthcare System, Boston, MA, USABoston University School of Medicine, Boston, MA, USA
Paul A Monach
Affiliation:
VA Boston Cooperative Studies Program, Boston, MA, USAHarvard Medical School, Boston, MA, USAVA Boston Healthcare System, Boston, MA, USA
Westyn Branch-Elliman*
Affiliation:
VA Boston Cooperative Studies Program, Boston, MA, USAGreater Los Angeles VA Healthcare System, Department of Medicine, Los Angeles, CA, USAUCLA David Geffen School of Medicine, Los Angeles, CA, USAVA Center for the Study of Healthcare Innovation, Implementation, and Policy, Los Angeles, CA, USA
*
Corresponding author: Westyn Branch-Elliman; Email: Westyn.Branch-Elliman@va.gov

Abstract

Background:

COVID-associated pulmonary aspergillosis (CAPA) was described early in the pandemic as a complication of SARS-CoV-2. Data about incidence of aspergillosis and characteristics of affected patients after mid-2021 are limited.

Methods:

A retrospective, nationwide cohort of US Veterans with SARS-CoV-2 from 1/1/2020 to 2/7/2024 was created. Potential cases of aspergillosis ≤12 weeks of a SARS-CoV-2 test were flagged electronically (based on testing results indicative of invasive fungal infection, antifungal therapy, and/or ICD-10 codes), followed by manual review to establish the clinical diagnosis of pulmonary aspergillosis. Incidence rates were calculated per 10,000 SARS-CoV-2 cases. Selected clinical characteristics included age >70, receipt of immune-compromising drugs, hematologic malignancy, chronic respiratory disease, vaccination status, and vaccine era. Multivariate logistic regression was used to estimate the independent effects of these variables via adjusted odds ratios (aOR).

Results:

Among 674,343 Veterans with SARS-CoV-2, 165 were electronically flagged for review. Of these, 66 were judged to be cases of aspergillosis. Incidence proportions ranged from 0.30/10,000 among patients with zero risk factors to 34/10,000 among those with ≥3 risk factors; rates were similar in the pre- and post-vaccination eras. The 90-day mortality among aspergillosis cases was 50%. In the multivariate analysis, immune suppression (aOR 6.47, CI 3.84–10.92), chronic respiratory disease (aOR 3.57, CI 2.10–6.14), and age >70 (aOR 2.78, CI 1.64–4.80) were associated with aspergillosis.

Conclusions:

Patients with underlying risk factors for invasive aspergillosis continue to be at some risk despite SARS-CoV-2 immunization. Risk in patients without immune suppression or preexisting lung disease is very low.

Information

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is a work of the US Government and is not subject to copyright protection within the United States. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America.
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© US Department of Veterans Affairs, 2025
Figure 0

Table 1.Characteristics of patients with SARS-CoV-2 infection who did or did not develop clinically-significant pulmonary aspergillosis from March 2020 through March 2024, and results of multivariate logistic regression—US Department of Veterans Affairs

Figure 1

Figure 1.Monthly incidence (total number of cases) of COVID-19 associated pulmonary aspergillosis (CAPA) from March 2020 through March 2024 (top panel) and the monthly incidence of SARS-CoV-2 infection during the same period (bottom panel)—US Department of Veterans Affairs.

Figure 2

Figure 2.Incidence of clinically significant pulmonary aspergillosis by the number of weeks after the positive test for SARS-CoV-2 (Panel A, only patients with aspergillosis, N = 66), and incidence of death by the number of weeks after the positive test for SARS-CoV-2 among patients with aspergillosis (Panel B) or all patients (Panel C). The data are intended to be descriptive and were not subjected to statistical analysis.

Figure 3

Figure 3.Incidence of Aspergillosis per 10,000 SARS-CoV-2 Infections, by Number of Risk Factors related to compromised immunity (transplantation, prior treatment with immune-compromising drugs, history of hematologic malignancy) or chronic respiratory disease). * Due to small numbers, 3 and 4 risk factors were combined into one category.

Supplementary material: File

Swinnerton et al. supplementary material

Swinnerton et al. supplementary material
Download Swinnerton et al. supplementary material(File)
File 33.6 KB